Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADVAX: SBRT with Nivolumab and Ipilimumab in Metastatic RCC
NCT03065179Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2017
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in metastatic renal cell carcinoma (mRCC), sponsored by UT Southwestern Medical Center. Started Mar 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03065179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065179.